posted on 2022-12-06, 18:40authored byDaryl J. Selen, Tanayott Thaweethai, Carolin C. M. Schulte, Sarah Hsu, Wei He, Kaitlyn James, Anjali Kaimal, James B. Meigs, Camille E. Powe
<p> </p>
<p><strong>Objective:</strong> Pregnant individuals are universally screened for gestational diabetes. Gestational glucose intolerance (GGI, an abnormal initial gestational diabetes screening test without a gestational diabetes diagnosis) is not a recognized diabetes risk factor. We tested for an association between GGI and diabetes after pregnancy.</p>
<p><strong>Research Design and Methods:</strong> We conducted a retrospective cohort study of individuals followed for prenatal and primary care. We defined GGI as an abnormal screening glucose loading test result at > 24 weeks’ gestation with an oral glucose tolerance test (OGTT) that did not meet gestational diabetes criteria. The primary outcome was incident diabetes. We used Cox proportional-hazard models with time-varying exposures and covariates to compare incident diabetes risk in individuals with GGI and normal glucose tolerance. </p>
<p><strong>Results:</strong> Among 16,836 individuals, 20,359 pregnancies had normal glucose tolerance, 2,943 had GGI, and 909 had gestational diabetes. Over a median of 8.4 years of follow-up, 428 individuals developed diabetes. Individuals with GGI had increased diabetes risk compared to those with normal glucose tolerance in pregnancy (adjusted hazard ratio, aHR [95% confidence interval, CI] 2.01[1.54-2.62], p<0.001). Diabetes risk increased with the number of abnormal OGTT values (zero: aHR 1.54[1.09-2.16], p=0.01; one: aHR 2.97[2.07-4.27], p<0.001; gestational diabetes: aHR 8.26[6.49-10.51], p<0.001; each compared to normal glucose tolerance). The fraction of diabetes 10 years after delivery attributable to GGI and gestational diabetes was 8.5% and 28.1%, respectively.</p>
<p><strong>Conclusion: </strong> GGI confers an increased risk of future diabetes. Routinely available clinical data identify an unrecognized group who may benefit from enhanced diabetes screening and prevention.<br>
<br>
</p>
Funding
Massachusetts General Hospital Claflin Distinguished Scholar Award Physician Scientist Development Award
U.S. Department of Health and Human Services > National Institutes of Health > National Institute of Diabetes and Digestive and Kidney Diseases T32DK007028 UM1DK078616